WntResearch AB (NGM: WNT)
Sweden
· Delayed Price · Currency is SEK 14.15
-0.25 (-1.74%)
At close: Sep 6, 2024
WntResearch AB Company Description
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process.
The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer.
It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer.
The company was incorporated in 2007 and is based in Lund, Sweden.
WntResearch AB
| Country | Sweden |
| Founded | 2007 |
| Industry | Other |
| Employees | 2 |
| CEO | Per Goran Norlen |
Contact Details
Address: Stora Södergatan 15 Lund, 222 23 Sweden | |
| Website | wntresearch.com |
Stock Details
| Ticker Symbol | WNT |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Per Goran Norlen | Chief Executive Officer |
| Anders Tidfors | Chief Financial Officer |
| Kicki Johansson | Chief Operating Officer |